Nascent Pharmaceuticals Adds Board Member
Posted July 17, 2006
RESEARCH TRIANGLE PARK, N.C. — Joanna Horobin, president and chief executive officer of Syndax Pharmaceuticals, has joined the board of directors at RTP-based
Nascent is focused on development of ophthalmology and oncology drugs. It is currently seeking a business development and commercialization partner for its lead drug to treat dry eye.
Syndax is a startup focused on treatment of cancer. Before joining that company, Horobin was entrepreneur in residence at MPM Capital, an investor in life sciences. She has also worked for several biotechnology firms.